Literature DB >> 8576329

Evaluation of Sanofi Diagnostics Pasteur Chlamydia Microplate EIA shortened assay and comparison with cell culture and Syva Chlamydia MicroTrak II EIA in high- and low-risk populations.

E L Chan1, K Brandt, G Horsman.   

Abstract

Seven hundred thirty-two female urogenital samples were collected for Chlamydia trachomatis testing by both the Sanofi Diagnostics Pasteur (Chaska, Minn.) Chlamydia Microplate EIA by the shortened protocol and the Syva (San Jose, Calif.) MicroTrak II EIA, and the results were compared with those obtained by cell culture. For the analysis of samples from female patients, the patients were divided into high- and low-risk categories. An additional 121 male urethral samples were collected and tested by the Sanofi Microplate EIA and cell culture; for the analysis of samples from male patients, the patients were divided into asymptomatic and symptomatic categories. All specimens positive by enzyme immunoassay (EIA) were confirmed by a blocking assay following the respective manufacturer's instructions. Specimens negative by EIA that fell within a gray zone 30% below the cutoff and negative cultures with one or more corresponding positive EIA results were tested further by cytocentrifugation and direct immunofluorescent assay. The overall sensitivity, specificity, positive predictive value, and negative predictive value for Syva versus culture were 94, 98.8, 85.5 and 99.6%, respectively. After resolution, the results were 94.5, 99.6, 94.5, and 99.6%, respectively. The parallel results for the Sanofi Microplate EIA versus culture were 94.0, 98.7, and 83.9, and 99.6%, respectively, and after being resolved, the results were 94.9, 100, 100, and 99.6%, respectively. In the small male population tested, the resolved results of the Sanofi Microplate EIA versus culture demonstrated sensitivity, specificity, positive predictive value, and negative predictive value of 100, 100, 100, and 100%, respectively. The present study demonstrated that the Sanofi Microplate EIA shortened protocol is highly sensitive and specific in comparison with cell culture and the Syva MicroTrak II EIA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576329      PMCID: PMC228590          DOI: 10.1128/jcm.33.11.2839-2841.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Chlamydia trachomatis in suburban adolescents.

Authors:  M Fisher; P D Swenson; D Risucci; M H Kaplan
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406

2.  Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix.

Authors:  J Schachter; W E Stamm; T C Quinn; W W Andrews; J D Burczak; H H Lee
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

3.  The use of a confirmatory assay to increase the sensitivity and specificity of the Chlamydiazyme test.

Authors:  E L Chan; K Brandt; D Kozoriz; L Mushanski; C Spence; G B Horsman
Journal:  Am J Clin Pathol       Date:  1994-12       Impact factor: 2.493

4.  The Chlamydia epidemic.

Authors:  K K Holmes
Journal:  JAMA       Date:  1981-05-01       Impact factor: 56.272

5.  Urinary leukocyte esterase screening test for asymptomatic chlamydial and gonococcal infections in males.

Authors:  M A Shafer; J Schachter; A B Moscicki; A Weiss; J Shalwitz; E Vaughan; S G Millstein
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

6.  Urinary leukocyte esterase screening for asymptomatic sexually transmitted disease in adolescent males.

Authors:  M J Werner; F M Biro
Journal:  J Adolesc Health       Date:  1991-06       Impact factor: 5.012

7.  Cost-effectiveness of screening women at moderate risk for genital infections caused by Chlamydia trachomatis.

Authors:  M D Nettleman; R B Jones
Journal:  JAMA       Date:  1988-07-08       Impact factor: 56.272

8.  Chlamydia trachomatis infections in the United States. What are they costing us?

Authors:  A E Washington; R E Johnson; L L Sanders
Journal:  JAMA       Date:  1987-04-17       Impact factor: 56.272

9.  Evaluation of three immunoassays for detection of Chlamydia trachomatis in urine specimens from asymptomatic males.

Authors:  G P Leonardi; M Seitz; R Edstrom; J Cruz; P Costello; K Szabo
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.

Authors:  A E Washington; P Katz
Journal:  JAMA       Date:  1991-11-13       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.